INS and diabetes mellitus: Nevertheless, in similar populations of people with diabetes in Boston, in a placebo-controlled randomized trial of 87 people, we were able to measure changes in FMD in response to troglitazone, an insulin-sensitizing agent (Caballero et al. 2003).